

# know error<sup>®</sup>

## Know Error and DNA Specimen Provenance Assignment Testing for Prostate Biopsies

*DNA testing that assures patient safety and diagnostic accuracy throughout the biopsy evaluation process*



*The person in personalized medicine.<sup>®</sup>*



## The Clinical Problem


The biopsy testing cycle for cancer can involve 18 different steps<sup>1</sup> performed at different locations each of which creates an opportunity for a switching or contamination error. Many of the steps are outside the control of a clinician and can lead to a Specimen Provenance Complication (SPC). If undetected the result may lead to the clinician assigning a cancer diagnosis to and treating the wrong patient. Thankfully, many of these SPCs can be discovered early and corrected before iatrogenic harm befalls the patient.

## DSPA Test

DNA Specimen Provenance Assignment (DSPA) testing is used to definitively assign specimen identity to the patient being evaluated. Patient misidentification, specimen transposition, and foreign cell contamination can be identified and resolved with Strand's DNA Specimen Provenance Assignment (DSPA) testing.

### The DSPA process

The patient's DNA is collected via cheek swab at the clinic and sent to Strand. The biopsy tissue specimen(s) is sent to Strand from the pathology laboratory. Strand performs the DSPA test by comparing the DNA profiles of the cheek swab to the biopsy tissue specimen. A report is then issued to the physician confirming a match or non-match of each specimen tested.



## Expect the Unknown

Data from Washington University published in the *American Journal of Clinical Pathology* indicate that **up to 3.5% of biopsies<sup>2</sup>** may be subject to **undetected** (occult) specimen provenance complications (SPCs) which could lead to a cancer diagnosis being assigned to the wrong patient. SPCs **occurred in every urology practice and pathology laboratory** evaluated in the study, concluding that **no one setting is immune from this problem of occult** errors.


## The Prospective Solution

Strand's patented **know error<sup>®</sup> system** can detect both suspected and unsuspected (occult) specimen provenance complications. The system includes a tissue collection kit which utilizes bar coding and forensic chain of custody principles in an effort to reduce errors in the sample collection process as well as incorporating the DSPA test to confirm that the biopsy specimen diagnosis is truly matched to the patient being evaluated. When used as part of routine clinical practice, it protects the entire diagnostic test cycle from otherwise occult errors and helps prevent adverse patient outcomes. Over 6% of prostate biopsies in U.S. are performed using the **know error<sup>®</sup> system**.



1. Bronner MP. DNA fingerprint analysis for specimen identification. *Clinical and Translational Pathology Research*. Div. of Pathology and Laboratory Medicine, Cleveland Clinic. 2006; Fall:5-7.  
 2. Pfeifer JD, Liu J. Rate of occult specimen provenance complications in routine clinical practice. Table 3. *Am J Clin Pathol*. 2013;139:93-100.





DNA testing that assures patient safety and diagnostic accuracy throughout the biopsy evaluation process



*The person in personalized medicine.®*



**Client Services**  
clientservices@knowerror.com  
888-924-6779, option 2

5770 Decatur Boulevard  
Indianapolis, IN 46241  
888-924-6779

[www.stranddiagnostics.com](http://www.stranddiagnostics.com)  
[www.knowerror.com](http://www.knowerror.com)

